Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, with a primary focus on pulmonary arterial hypertension (PAH). The IKT news feed highlights the company’s progress as it advances its lead investigational therapy, IKT-001, a prodrug of imatinib mesylate, through late-stage clinical development in PAH.
Visitors to this page can review company-issued press releases and related disclosures that describe Inhibikase’s clinical plans, regulatory interactions, and corporate developments. Recent news has covered the evolution of the IMPROVE-PAH clinical program for IKT-001, including the transition from a planned Phase 2b trial to a global pivotal Phase 3 study design following a Type C interaction with the U.S. Food & Drug Administration. The company also reports on its financial results, capital raises through private placements and underwritten public offerings, and changes in senior leadership and board composition.
Because Inhibikase is a clinical-stage company with no marketed products, its news flow is closely tied to research and development milestones, such as study protocol finalization, anticipated trial initiation timelines, and updates on the design of adaptive clinical studies in PAH. Corporate updates, including executive appointments and governance matters, are also reflected in its announcements. Investors and observers can use this news page to follow how Inhibikase describes the advancement of IKT-001 in pulmonary arterial hypertension and how the company positions itself within the cardiopulmonary disease space.
Inhibikase Therapeutics reported its Q1 2024 financial results and recent developments. The net loss for Q1 2024 was $4.6 million ($0.73 per share), slightly higher than Q1 2023's $4.5 million ($0.98 per share). R&D expenses decreased to $2.8 million from $2.9 million, primarily due to reduced costs for IkT-001Pro, while SG&A expenses increased to $2.0 million from $1.9 million.
The Phase 2 trial for Risvodetinib in Parkinson's disease is 83% enrolled, with final enrollment expected in June 2024. The company completed Pre-NDA and Pre-IND meetings with the FDA for IkT-001Pro, targeting oncology and pulmonary arterial hypertension. Cash reserves stand at $9.7 million, projected to fund operations through November 2024.
Inhibikase will host a conference call on May 16, 2024, at 8:00 a.m. ET to discuss these results.
Inhibikase Therapeutics announced the withdrawal of its Registration Statement on Form S-1, initially filed with the SEC on April 19, 2024. The company confirmed that the S-1 had not yet been declared effective and that no securities were sold related to this filing. This action reflects a strategic decision not to proceed with the offering at this time. The press release clarifies that this announcement does not constitute an offer to sell or solicit offers to buy any securities of the company.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced outcomes from the final pre-IND meeting with the FDA for IkT-001Pro as a treatment for Pulmonary Arterial Hypertension. The FDA designated IkT-001Pro as a New Molecular Entity, allowing for exclusivity designations. The Company is preparing the IND application for Pro, a potential branded product for PAH, a deadly disease with treatment options.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.